Meta-Analysis
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 348-361
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.348
Table 1 Characteristics of the included studies, n (%)
Ref.
Magazine
Design
Study type
Surveillance period
Sources of patients
Race
Age at IBD diagnosis(years)
IBD type
IBD with/without PIPs
Male gender (%)
Outcome
de Jong et al[31], 2020Inflamm Bowel DisRetrospectiveCohortJanuary 2012 -December 2017The NetherlandsCaucasian28.5 (± 11.8)/28.9 (± 12.4)1Mixed IBD154/365284 (48.2)Neoplasia
Gu et al[35], 2019Journal of Digestive DiseasesRetrospective CohortJune 1986 -July 2018ChinaAsian29.5-54.0UC57/189120 (48.8)Neoplasia
Mahmoud et al[32], 2019GastroenterologyRetrospectiveCohortJanuary 1997 - January 2017America, The NetherlandsCaucasianNAMixed IBD462/1120835 (52.8)Neoplasia
Ünal et al[34], 2019Turkish Journal of GastroenterologyRetrospectiveCohort1993-2016TurkeyAsian40.5 ± 15UC100/701475 (59.3)Neoplasia
Ma et al[36], 2017Laboratory InvestigationRetrospectiveCohort2006-2016NANANAMixed IBD102/220NANeoplasia
Jegadeesan et al[37], 2016Inflamm Bowel DisRetrospectiveCase–control1998-2011AmericaCaucasian37 (30.5–50.5)/38 (28.2–23.4)2UC138/329251 (53.7)Neoplasia
Lutgens et al[38], 2015Clinical Gastroenterology and HepatologyRetrospectiveCase–control1990-2011Belgium, The NetherlandsCaucasianNAMixed IBD259/271276 (52.1)Cancer
Badamas et al[40], 2014GastroenterologyRetrospectiveCase–control2007-2013NANA30.3 (± 15.6)/29.3 (± 13.2)Mixed IBD90/9393 (50.8)Neoplasia
Freire et al[39], 2014Scand J GastroenterolProspectiveCross-sectionalApril 2011 -December 2013PortugalCaucasian33.3 ± 11.6UC33/4330 (39.5)Neoplasia
Baars et al[41], 2011Am J GastroenterolRetrospectiveCase – controlJanuary 1990 – July 2006The NetherlandsCaucasianNAMixed IBD147/366266 (47.1)Cancer
Velayos et al[29], 2006GastroenterologyRetrospectiveCase – controlJanuary 1976 -December 2002AmericaCaucasian25 (6–76)/27 (8–66)UC184/192266 (70.7)Cancer
Rutter et al[14], 2004GutRetrospectiveCase – controlJanuary 1988 - January 2002BritainCaucasian33 (6–65)UC95/109117 (57)Neoplasia
1Data expressed as mean ± SD.
2Data expressed as median (range).
IBD: Inflammatory bowel disease; PIPs: Post-inflammatory polyps; UC: Ulcerative colitis; NA: Not available.
Table 2 Assessment of the quality of studies
Ref.Selection
Comparability
Outcome
1
2
3
4
5
6
7
8
Score
de Jong et al[31], 2020b1a1a1a1a b2a1a1a19
Gu et al[35], 2019b1a1da1a b2a1a1a18
Mahmoud et al[32], 2019b1a1a1a1a b2a1a1a19
Ünal et al[34], 2019b1a1da1a b2a1a1a18
Ma et al[36], 2017da1a1a1a b2dcd5
Jegadeesan et al[37], 2016a1a1ba1a b2a1a1a18
Lutgens et al[38], 2015a1bba1a b2a1a1a17
Badamas et al[40], 2014a1a1ba1a b2a1a1b7
Freire et al[39], 2014a1bba1a b2ea1a16
Baars et al[41], 2011a1a1ba1a b2ea1a17
Velayos et al[29], 2006a1a1ba1a b2a1a1a18
Rutter et al[14], 2004a1a1ba1a b2a1a1a18
1Data expressed as mean ± SD.
2Data expressed as median (range). The quality of studies was assessed using the Newcastle-Ottawa Scale (Supplementary Table 1). A high-quality study required a score of 7 or above.
Table 3 Results of the sensitivity analysis in the impact of each study on the overall risk estimate
Ref.
Odds Ratio
95% Confidence Interval
Heterogeneity (I²)
de Jong et al[31], 20202.0980003[1.443344, 3.0495887]76%
Gu et al[35], 20191.8818157[1.3357893, 2.6510394]75%
Mahmoud et al[32], 20192.1335025[1.4797615, 3.0760586]73%
Ünal et al[34], 20192.0057204[1.406724, 2.8597751]77%
Ma et al[36], 20172.0393412[1.4283487, 2.9116926]77%
Jegadeesan et al[37], 20162.1974959[1.5660043, 3.0836365]71%
Lutgens et al[38], 20151.8946518[1.3246907, 2.7098444]73%
Badamas et al[40], 20141.9649121[1.3789148, 2.7999403]77%
Freire et al[39], 20142.1011214[1.4932369, 2.9564707]76%
Baars et al[41], 20111.8324436[1.326488, 2.5313833]67%
Velayos et al[29], 20062.0466876[1.3896827, 3.014307]77%
Rutter et al[14], 20041.9644971[1.35726, 2.8434114]77%
Combined2.011362[1.4304829, 2.82812]75%